THE boom in Global Capability Centres (GCCs) is rapidly transforming India from a “support base” into a strategic innovation engine for pharma and medtech. Nearly half of the world’s top 50 life sciences companies have set up GCCs in India in just the past five years. GCCs in India handle 45% of global drug discovery and development man-dates, 60% of regulatory affairs, and 54% of medical affairs for their parent companies. They are leading clinical trials, pharmacovigilance, digital therapeutics, and real-world evidence analytics, often powered by Al.